A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center

Launched by METHODIST HEALTH SYSTEM · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at patients with Hepatorenal Syndrome (HRS), a serious condition that affects the kidneys in people with liver disease. The study will analyze data from patients who were hospitalized at Methodist Dallas Medical Center between April 1, 2019, and April 1, 2023, to better understand how HRS impacts kidney function and what factors might contribute to it. Eligible participants are adults over 18 years old who either had HRS at the time of their hospital admission or developed it during their stay.

If you or a loved one qualifies for this study, you won’t need to do anything different as this is a retrospective analysis, meaning researchers will look back at existing medical records. Your participation could help improve understanding of HRS and potentially lead to better treatments for future patients. It's important to note that patients under 18 or those without a diagnosis of HRS during the specified timeframe will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * All patients \>18 years old that were hospitalized between April 1st 2019 and April 1st 2023 who either presented with HRS-AKI or developed a diagnosis of HRS during the hospital course. HRS-AKI will be defined based on the ICA criteria, described below:
• • 1. Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure
• • 2. An increase in serum Cr of ≥0.3 mg/dL within 48 hours or ≥50% from baseline value and/or urinary output ≤0.5 mL/kg of body weight for ≥6 hours (requires use of a urinary catheter)
• • 3. No full or partial response for ≥2 days of diuretic withdrawal and volume expansion with albumin (dosed at 1 g/kg of body weight/day)
• • 4. Absence of shock
• • 5. No current or recent treatment with nephrotoxic drugs
• • 6. Absence of parenchymal renal disease
• • 7. Suggestion of renal vasoconstriction based on FENa \<0.2%
• Exclusion Criteria:
• • 1. HRS-AKI patients \<18 years of age 2. All patients hospitalized between April 1st 2019 and April 1st 2023 without a diagnosis of HRS-AKI.